Next Generation Vaccine Platform
Vaccine Platform with Multiple Antigen Display
Full Protection in 1-2 Doses
Multiple Antigen Display
Easy to Modify
Monomer
Complex Formation
VaxSyna's vaccine platform can be utilized to create both prophylactic and therapeutic vaccines
Our patented vaccine platform is made up of a human IgG antibody fused to a target vaccine antigen and an epitope tag specific to the vaccine platform's antibody. This configuration enables higher-order antibody complexes that trigger the immune response through Fc-Receptor binding and crosslinking. The platform is easily modified to any size target antigen and multiple antigens can be displayed on either the C- or N- terminus of the platform IgG.
Plant Manufacturing
Expression System
Reduced manufacturing costs
High Yield ~100g/kg fresh leaf weight
Expression in 4-5 days
No human or animal pathogens
VaxSyna’s expression platform can be utilized to produce a wide range of recombinant proteins
VaxSyna’s expression system is based on a geminiviral vector delivered into Nicotiana benthamiana leaves. This platform uses a deconstructed geminiviral genome to drive transient expression of proteins for efficient and scalable protein production. Within 4–5 days post-infiltration, plants can yield up to 100g of protein per kilogram of leaf tissue, significantly reducing development timelines. The plant-based system offers reduced early-stage manufacturing costs compared to traditional cell culture methods, eliminates the risk of human or animal pathogen contamination, and enables linear scale-up. Additionally, N. benthamiana supports human-like glycosylation.